No retraction, correction or concern found when last checked on Oct 26, 2026.

Metformin attenuates silica-induced pulmonary fibrosis via AMPK signaling

Demin Cheng, Qi Xu, Yue Wang and 7 more

Journal of Translational Medicine · 2021 · CC BY

Abstract

Background. Silicosis is one of the most common occupational pulmonary fibrosis caused by respirable silica-based particle exposure, with no ideal drugs at present. Metformin, a commonly used biguanide antidiabetic agent, could activate AMP-activated protein kinase (AMPK) to exert its pharmacological action. Therefore, we sought to investigate the role of metformin in silica-induced lung fibrosis.

Methods. The anti-fibrotic role of metformin was assessed in 50 mg/kg silica-induced lung fibrosis model. Silicon dioxide (SiO2)-stimulated lung epithelial cells/macrophages and transforming growth factor-beta 1 (TGF-β1)-induced differentiated lung fibroblasts were used for in vitro models.

Results. At the concentration of 300 mg/kg in the mouse model, metformin significantly reduced lung inflammation and fibrosis in SiO2-instilled mice at the early and late fibrotic stages. Besides, metformin (range 2–10 mM) reversed SiO2-induced cell toxicity, oxidative stress, and epithelial-mesenchymal transition process in epithelial cells (A549 and HBE), inhibited inflammation response in macrophages (THP-1), and alleviated TGF-β1-stimulated fibroblast activation in lung fibroblasts (MRC-5) via an AMPK-dependent pathway.

Conclusions. In this study, we identified that metformin might be a potential drug for silicosis treatment.

Supplementary Information. The online version contains supplementary material available at 10.1186/s12967-021-03036-5.

References 82

1.
Cao Z, et al. A novel pathophysiological classification of silicosis models provides some new insights into the progression of the disease. Ecotoxicol Environ Saf. 2020;202:110834.
Not in our library10.1016/j.ecoenv.2020.110834
2.
Xie Y, Ma J, Yang M, Fan L, Chen W. Extracellular signal-regulated kinase signaling pathway and silicosis. Toxicol Res. 2021;10(3):487-494.
Not in our library10.1093/toxres/tfaa109
3.
Feng F, et al. The protective role of tanshinone IIA in silicosis rat model via TGF-beta1/Smad signaling suppression, NOX4 inhibition and Nrf2/ARE signaling activation. Drug Des Devel Ther. 2019;13:4275-4290.
Not in our library10.2147/dddt.s230572
4.
Hoy R, Chambers DC. Silicosis: an ancient disease in need of a dose of modern medicine. Respirology. 2020;25(5):464-465.
Not in our library10.1111/resp.13766
5.
Wollin L, et al. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J. 2019.
Not in our library10.1183/13993003.00161-2019
6.
Fang S, et al. circHECTD1 promotes the silica-induced pulmonary endothelial-mesenchymal transition via HECTD1. Cell Death Dis. 2018;9(3):396.
Not in our library10.1038/s41419-018-0432-1
7.
Li Y, et al. M10 peptide attenuates silica-induced pulmonary fibrosis by inhibiting Smad2 phosphorylation. Toxicol Appl Pharmacol. 2019;376:46-57.
Not in our library10.1016/j.taap.2019.05.015
8.
YY1 mediates TGF-β1-induced EMT and pro-fibrogenesis in alveolar epithelial cells · 2019
No notice
9.
Li X, et al. Antifibrotic mechanism of cinobufagin in bleomycin-induced pulmonary fibrosis in mice. Front Pharmacol. 2019;10:1021.
Not in our library10.3389/fphar.2019.01021
10.
Chen YC, et al. Particulate matters increase epithelial-mesenchymal transition and lung fibrosis through the ETS-1/NF-kappaB-dependent pathway in lung epithelial cells. Part Fibre Toxicol. 2020;17(1):41.
Not in our library10.1186/s12989-020-00373-z
11.
Deng Y, Chakraborty P, Jolly MK, Levine H. A theoretical approach to coupling the epithelial-mesenchymal transition (EMT) to extracellular matrix (ECM) stiffness via LOXL2. Cancers. 2021.
Not in our library10.3390/cancers13071609
12.
The Role of NLRP3 Inflammasome Activation in the Epithelial to Mesenchymal Transition Process During the Fibrosis · 2020
Not checked
13.
Lopes-Pacheco M, Bandeira E, Morales MM. Cell-based therapy for silicosis. Stem Cells Int. 2016;2016:5091838.
Not in our library10.1155/2016/5091838
14.
The Lung Macrophage in SARS-CoV-2 Infection: A Friend or a Foe? · 2020
No notice
15.
Gao R, et al. Macrophage-derived netrin-1 drives adrenergic nerve-associated lung fibrosis. J Clin Invest. 2021.
Not in our library10.1172/jci136542
16.
Du S, et al. Dioscin alleviates crystalline silica-induced pulmonary inflammation and fibrosis through promoting alveolar macrophage autophagy. Theranostics. 2019;9(7):1878-1892.
Not in our library10.7150/thno.29682
17.
Xu T, et al. MiR-326 inhibits inflammation and promotes autophagy in silica-induced pulmonary fibrosis through targeting TNFSF14 and PTBP1. Chem Res Toxicol. 2019;32(11):2192-2203.
Not in our library10.1021/acs.chemrestox.9b00194
18.
Takenouchi Y, Kitakaze K, Tsuboi K, Okamoto Y. Growth differentiation factor 15 facilitates lung fibrosis by activating macrophages and fibroblasts. Exp Cell Res. 2020;391(2):112010.
Not in our library10.1016/j.yexcr.2020.112010
19.
Lin S, et al. LncRNA Hoxaas3 promotes lung fibroblast activation and fibrosis by targeting miR-450b-5p to regulate Runx1. Cell Death Dis. 2020;11(8):706.
Not in our library10.1038/s41419-020-02889-w
20.
Maniar K, Moideen A, Mittal A, Patil A, Chakrabarti A, Banerjee D. A story of metformin-butyrate synergism to control various pathological conditions as a consequence of gut microbiome modification: Genesis of a wonder drug? Pharmacol Res. 2017;117:103-128.
Not in our library10.1016/j.phrs.2016.12.003
21.
Li J, et al. Metformin limits osteoarthritis development and progression through activation of AMPK signalling. Ann Rheum Dis. 2020;79(5):635-645.
Not in our library10.1136/annrheumdis-2019-216713
22.
Liu J, et al. Metformin suppresses proliferation and invasion of drug-resistant breast cancer cells by activation of the Hippo pathway. J Cell Mol Med. 2020;24(10):5786-5796.
Not in our library10.1111/jcmm.15241
23.
The mechanisms of action of metformin · 2017
No notice
24.
Bland AR, Shrestha N, Bower RL, Rosengren RJ, Ashton JC. The effect of metformin in EML4-ALK+ lung cancer alone and in combination with crizotinib in cell and rodent models. Biochem Pharmacol. 2021;183:114345.
Not in our library10.1016/j.bcp.2020.114345
25.
Jalali M, et al. The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis: an up-to date systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2020;159:104799.
Not in our library10.1016/j.phrs.2020.104799
26.
Guo Y, et al. Metformin alleviates allergic airway inflammation and increases Treg cells in obese asthma. J Cell Mol Med. 2021.
Not in our library10.1111/jcmm.16269
27.
Crowley MJ, et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Ann Intern Med. 2017;166(3):191-200.
Not in our library10.7326/m16-1901
28.
Metformin and Its Benefits for Various Diseases · 2020
No notice
29.
Maniar K, Singh V, Moideen A, Bhattacharyya R, Chakrabarti A, Banerjee D. Inhalational supplementation of metformin butyrate: a strategy for prevention and cure of various pulmonary disorders. Biomed Pharmacother. 2018;107:495-506.
Not in our library10.1016/j.biopha.2018.08.021
30.
Xiao H, et al. Metformin ameliorates bleomycin-induced pulmonary fibrosis in mice by suppressing IGF-1. Am J Transl Res. 2020;12(3):940-949.
Not in our library
31.
Rangarajan S, et al. Metformin reverses established lung fibrosis in a bleomycin model. Nat Med. 2018;24(8):1121-1127.
Not in our library10.1038/s41591-018-0087-6
32.
van Kammen-Wijnmalen EH, ten Brink HD, Hendriks D, Drion EF. Prevelance of pneumoconiosis in diabetic coal-miners. A preliminary report. J Chronic Dis. 1970;22(8):609-615.
Not in our library10.1016/0021-9681(70)90037-8
33.
Matsumoto N, et al. Butyrate modulates TGF-beta1 generation and function: potential renal benefit for Acacia(sen) SUPERGUM (gum arabic)? Kidney Int. 2006;69(2):257-265.
Not in our library10.1038/sj.ki.5000028
34.
Cheng D, et al. Long noncoding RNA-SNHG20 promotes silica-induced pulmonary fibrosis by miR-490-3p/TGFBR1 axis. Toxicology. 2021.
Not in our library10.1016/j.tox.2021.152683
35.
Ma J, et al. A positive feed forward loop between Wnt/beta-catenin and NOX4 promotes silicon dioxide-induced epithelial-mesenchymal transition of lung epithelial cells. Oxid Med Cell Longev. 2020;2020:3404168.
Not in our library10.1155/2020/3404168
36.
Mitochondrial quality control in pulmonary fibrosis · 2020
Not checked
37.
The Role of Glutathione in Protecting against the Severe Inflammatory Response Triggered by COVID-19 · 2020
No notice
38.
Guo X, et al. The AMPK-PGC-1alpha signaling axis regulates the astrocyte glutathione system to protect against oxidative and metabolic injury. Neurobiol Dis. 2018;113:59-69.
Not in our library10.1016/j.nbd.2018.02.004
39.
Santana PT, et al. P2Y12 receptor antagonist clopidogrel attenuates lung inflammation triggered by silica particles. Front Pharmacol. 2020;11:301.
Not in our library10.3389/fphar.2020.00301
40.
Dissecting the role of AMP-activated protein kinase in human diseases · 2017
Not checked

All 82 references

Cited by papers we hold 1

Overview of the Mechanisms of Oxidative Stress: Impact in Inflammation of the Airway Diseases · 2022
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.